Champions Oncology Inc

Champions Oncology Inc, based in Rockville, is a leading provider of innovative solutions for oncology research and preclinical drug development. The company specializes in patient-derived xenografts, offering cutting-edge services to advance cancer treatment and drug discovery. Generated from their website's infomation

Incorporated in 1989, Otsuka America Pharmaceutical is a health care company that commercializes its products throughout North America. It offers products under the ABILIFY Tablets1 and PLETAL Tablets2 brands. The company works in collaboration with Bristol-Myers Squibb, which co-develops and co-promotes ABILIFY. Otsuka America Pharmaceutical has also merged with Meretek Diagnostics to form the Meretek Diagnostics Group under the Medical Device Division of OAPI. It focuses on neuroscience, cardiovascular, oncologic and gastrointestinal therapeutic treatments. The company operates Otsuka Maryland Research Institute, which was established as a wholly-owned subsidiary of OAPI to research and develop a variety of health care products. Otsuka America Pharmaceutical is a part of Otsuka Pharmaceutical Group.

GlycoMimetics develops novel small molecule therapeutics based upon the roles that carbohydrates play in biological processes. The company believes that carbohydrate mimics, or glycomimetic compounds, represent a new class of drugs. It has identified some compounds with potential therapeutic utility. One class has potential in the treatment of infectious diseases with a novel mechanism of action; the second is a class of anti-inflammatory compounds that have been shown to reduce key measures of inflammation. One of GMI s lead opportunities is to treat or prevent infections caused by Pseudomonas aeruginosa. Its objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections that have failed to respond to antibiotic treatment. The company also has compounds that inhibit selectin binding. Its initial focus in this program is to develop a product to treat acute exacerbations of asthma and chronic obstructive pulmonary disease. GlycoMimetics is headquartered in Gaithersburg, Md.